Tamoxifen
- PDF / 169,126 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 66 Downloads / 147 Views
1 S
Ovarian hyperstimulation: 19 case reports In a study of 205 women diagnosed with breast cancer between March 2012 and December 2016, 19 adult women [exact ages not stated] were described, who developed ovarian hyperstimulation during an adjuvant endocrine therapy with tamoxifen [routes and times to reactions onset not stated]. The women, who were diagnosed with hormone-dependent breast cancer, underwent surgery. Post-operatively, the women were scheduled to receive tamoxifen 20mg daily for 5 years as an adjuvant endocrine therapy. During the tamoxifen therapy, the women exhibited elevated levels of serum estradiol. Eventually, tamoxifen-induced ovarian hyperstimulation was diagnosed. However, tamoxifen therapy was continued. Subsequently, the women showed normal serum estradiol levels in 48 months. Kim MK, et al. Risk Factors for Tamoxifen-Induced Ovarian Hyperstimulation in Breast Cancer Patients. Clinical Breast Cancer 20: 408-412, No. 5, Oct 2020. Available 803514191 from: URL: http://doi.org/10.1016/j.clbc.2020.01.003
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
